AstraZeneca And Amgen's TEZSPIRE Met Co-Primary Endpoints In Phase III EoE Trial

First and only biologic therapy to achieve statistically significant and clinically meaningful histologic remission and symptom improvements at week 24 that were sustained through week 52 vs. placebo

TEZSPIRE attained statistically significant total endoscopic remission with visible clearance of inflammation and fibrosis, vs. placebo at week 52

Full results from the positive Phase III CROSSING trial showed that AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab) demonstrated statistically significant and clinically meaningful improvements in the co-primary endpoints of histologic remission and the frequency and severity of dysphagia (difficulty swallowing) in adolescent and adult patients with symptomatic and uncontrolled eosinophilic esophagitis (EoE), despite continued treatment with background medications. These improvements were observed at week 24 in both doses tested compared to placebo.1 Efficacy was sustained in both doses through week 52, as measured in key secondary endpoints.

Results from the CROSSING trial were presented in a late-breaking oral presentation at United European Gastroenterology Week 2026 in Barcelona, Spain.

Treatment withTEZSPIRE, administered subcutaneously every four weeks, achieved histologic remission for 64.8% (210mg dose) and 68.9% (420mg dose) of patients at week 24, compared to 3.5% of patients on placebo (p<0.001). TEZSPIRE also reduced the frequency and severity of dysphagia symptoms by 18.8 points (210mg dose; p=0.049) and 22.0 points (420mg dose; p<0.001) from baseline vs. 14.7 points on placebo, as measured by the Dysphagia Symptom Questionnaire (DSQ) score, a patient-reported outcome measure.1 These results were sustained through week 52, assessed in key secondary endpoints: 67.8% (210mg dose) and 63.3% (420mg dose) of patients taking TEZSPIRE achieved histologic remission vs. 5.4% on placebo (p<0.001) and there was continued symptom improvement through week 52, with patients taking TEZSPIRE achieving an average reduction from baseline of 22.1 points (210mg dose) and 24.0 points (420mg dose) in the DSQ score vs. 13.2 points on placebo (p < 0.001).

In key secondary endpoints, treatment with TEZSPIRE resulted in statistically significant improvements in endoscopic features and severity (measured with the EoE Endoscopic Reference Score, or "EREFS") at weeks 24 and 52.1 Additionally, 34.4% (210mg dose) and 29.5% (420mg dose) of patients achieved total endoscopic remission, meaning no visible features of EoE at week 52 (vs. 4.1% placebo (p<0.001)), as measured in a key secondary endpoint.

In patients with EoE, inflammation of the esophagus can lead to dysphagia, food impaction and esophageal narrowing, and the risk of food moving slowly or becoming stuck can make daily meals difficult and stressful. Nearly half of patients, including adolescents, do not achieve adequate disease control with current standard of care designed to manage symptoms, which include dietary restriction, swallowed topical corticosteroids and proton pump inhibitors.